|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 2007;83:221-222
© 2007 The Society of Thoracic Surgeons
Department of Surgery, Duke University Medical Center, Box 3496, Duke South Room 3589, Durham, NC 27710
(Email: damic001@mc.duke.edu).
| The first 20% of the full text of this article appears below. |
The use of molecular techniques in the staging of malignancy (ie, molecular biologic substaging) may improve the assessment of prognosis and the assignment of therapy for patients with nonsmall cell lung cancer (NSCLC). The current staging system tends to under-stage patients, and clinical staging is even less accurate than pathologic staging. Molecular biologic substaging may be applied to the primary tumor to assess prognosis or chemoresistance, and to lymph nodes, serum, or bone marrow to assess occult systemic metastases.
If it were possible to identify which patients
Related Article
Ann. Thorac. Surg. 2007 83: 216-221.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |